Anti-angiogenic agents, such as VEGF (e.g., bevacizumab) and multi-tyrosine kinase (e.g., sorafenib) inhibitors, have been investigated for their ability to normalize the tumor vasculature, enhance drug delivery, and improve the efficacy of immunotherapy [88]. This evidence concerns the gene VEGFA and neoplasm.